148 related articles for article (PubMed ID: 8160137)
1. [The use of reaferon in treating patients with protracted viral hepatitis].
Kokoreva LN; Zmyzgova AV; Nazarenko IV
Ter Arkh; 1994; 66(2):21-4. PubMed ID: 8160137
[TBL] [Abstract][Full Text] [Related]
2. [Reaferon treatment in acute HBsAG-positive viral hepatitis].
Gorbarets IP; Ketiladze ES; Farber NA; Bugaeva NP; Braginskiĭ DM
Klin Med (Mosk); 1990 Mar; 68(3):65-8. PubMed ID: 2370758
[TBL] [Abstract][Full Text] [Related]
3. [The interferon therapy of patients with chronic viral hepatitis: the factors affecting the treatment results].
Kokoreva LN; Zmyzgova AV; Shalygina NB
Ter Arkh; 1996; 68(2):10-4. PubMed ID: 8771646
[TBL] [Abstract][Full Text] [Related]
4. [The treatment of different forms of B and delta hepatitis with interferon preparations].
Botsvadze ESh; Kuznetsov VP; Aleksishvili MM; Gogichaĭshvili ShSh
Ter Arkh; 1991; 63(11):61-3. PubMed ID: 1810067
[TBL] [Abstract][Full Text] [Related]
5. [The dynamic production of interferons, interleukins and arachidonic acid metabolites by the blood cells of children with glomerulonephritis associated with HB virus infection while treated with reaferon].
Markarian AS; Malinovskaia VV; Dlin VV; Ignatov MS; Asratian AA; Pronin AV
Vopr Virusol; 1993; 38(4):152-6. PubMed ID: 7694426
[TBL] [Abstract][Full Text] [Related]
6. [Reaferon and interferonogenes in the therapy of acute viral hepatitis B].
Andreĭchin MA; Zmyzgova AV; Rudchik AS
Klin Med (Mosk); 1991 Mar; 69(3):77-80. PubMed ID: 2067345
[TBL] [Abstract][Full Text] [Related]
7. [The problem of the interferon therapy of patients with chronic viral hepatitis].
Kokoreva LN; Zmyzgova AV; Shalygina NB
Zh Mikrobiol Epidemiol Immunobiol; 1995; (5):101-4. PubMed ID: 8525715
[TBL] [Abstract][Full Text] [Related]
8. [The clinico-morphological characteristics and efficacy of interferon therapy in patients with chronic delta hepatitis].
Kokoreva LN; Zmyzgova AV; Shalygina NB; Maksimov SL
Zh Mikrobiol Epidemiol Immunobiol; 1994; (1):55-9. PubMed ID: 8184615
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study.
Manesis EK; Vourli G; Dalekos G; Vasiliadis T; Manolaki N; Hounta A; Koutsounas S; Vafiadis I; Nikolopoulou G; Giannoulis G; Germanidis G; Papatheodoridis G; Touloumi G
J Hepatol; 2013 Nov; 59(5):949-56. PubMed ID: 23850875
[TBL] [Abstract][Full Text] [Related]
10. [Chronic hepatitis delta--the course and approaches to therapy].
Blokhina NP; Ketiladze ES; Kelli EI; Viazov SO
Klin Med (Mosk); 1991 Mar; 69(3):85-8. PubMed ID: 2067348
[TBL] [Abstract][Full Text] [Related]
11. [Use of interferon inducers and reaferon in the combined therapy of acute viral hepatitis B].
Andreĭchin MA; Rudchik AS; Borak VF
Ter Arkh; 1988; 60(11):29-32. PubMed ID: 3238572
[TBL] [Abstract][Full Text] [Related]
12. Recombinant alpha 2c-interferon therapy in fulminant viral hepatitis.
Sánchez-Tapias JM; Mas A; Costa J; Bruguera M; Mayor A; Ballesta AM; Compernolle C; Rodés J
J Hepatol; 1987 Oct; 5(2):205-10. PubMed ID: 3693864
[TBL] [Abstract][Full Text] [Related]
13. [The reaferon treatment of a patient with acute viral hepatitis B and hemorrhagic vasculitis].
Fedorchenko SV; Tereshchenko TM
Vrach Delo; 1990 Oct; (10):104-5. PubMed ID: 2080557
[No Abstract] [Full Text] [Related]
14. [The effect of recombinant alfa-2 interferon (reaferon) on the functional activity of natural killers in acute viral hepatitis B].
Petrovskaia IA; Kushko LIa; Fedorchenko SV; Vovk AD; Listopad NK; Antoniak SN; Drannik GN
Zh Mikrobiol Epidemiol Immunobiol; 1995; (6):56-7. PubMed ID: 8553758
[No Abstract] [Full Text] [Related]
15. [Approaches to perfection of Reaferon therapy in hepatitis B].
Korochkina OV
Klin Med (Mosk); 1996; 74(4):22-3. PubMed ID: 8999144
[No Abstract] [Full Text] [Related]
16. [Activation of the interferon system enzymes by recombinant alpha2-interferon in patients with chronic hepatitis B].
Sokolova TM; Bugaeva NP; Suetina IA; Ershov FI; Ketiladze ES
Antibiot Khimioter; 1989 Jun; 34(6):472-5. PubMed ID: 2552947
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cell function during interferon treatment of delta hepatitis.
Actis GC; Maran E; Saracco G; Rosina F; Baldi M; Brunetto M
Prog Clin Biol Res; 1987; 234():305-8. PubMed ID: 3628385
[No Abstract] [Full Text] [Related]
18. Alpha interferon plus thymopentine in treatment of HBV and/or HDV positive patients undergoing liver transplant.
Gaeta A; Mancini C; Bachetoni A; Sallusto F; Lorino G; Marinucci G; Di Giacomo C; Favalli C; Alfani D; Filadoro F
J Biol Regul Homeost Agents; 1990; 4(2):51-6. PubMed ID: 2260503
[TBL] [Abstract][Full Text] [Related]
19. [Recombinant alpha2-interferon substances in treating patients with acute hepatitis B with a mild course].
Malinovskaia VV; Neumoina MV; Bragina GS
Vopr Virusol; 1997; 42(4):182-5. PubMed ID: 9304301
[TBL] [Abstract][Full Text] [Related]
20. [Change in interferon status in patients with acute viral hepatitis during intramuscular and rectal administration of genetically engineered alpha-2-interferon].
Malinovskaia VV; Neumoina MV; Budanov SV
Vopr Virusol; 1994; 39(6):269-72. PubMed ID: 7536374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
